<DOC>
	<DOCNO>NCT00464633</DOCNO>
	<brief_summary>Multicenter , open-label , study alvocidib previously treat chronic lymphocytic leukemia patient . Primary objective determine overall response rate . The secondary objective : - ass overall safety , - ass duration response , progression free survival , overall survival . Clinical benefit pharmacokinetics parameter also evaluate .</brief_summary>
	<brief_title>Alvocidib Patients With Previously Treated Chronic Lymphocytic Leukemia Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description>Treatment disease progression evidence treatment response ; occurrence unacceptable toxicity , intercurrent medical problem , adverse event ( AE ) ; maximum 6 cycle . Follow-up 6 month last treatment alvocidib . The maximum duration study participation patient 15 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic</mesh_term>
	<mesh_term>Alvocidib</mesh_term>
	<criteria>Patient must documentation histologically confirm measurable Chronic Lymphocytic Leukemia ( CLL ) Prolymphocytic Leukemia ( PLL ) arise CLL ; Patient must symptomatic progressive disease ; Patient must receive prior alkylating agent ( ) fludarabine refractory ; Patient must adequate organ function ; Patient 's Eastern Cooperative Oncology Group performance ( ECOG ) status must 02 ; Patient de novo PLL ; Patient secondary malignancy limit survival ≤5 year ; Patient prior allogenic autologous bone marrow transplant peripheral blood stem cell transplant ≤12 month ; Patient receive investigational agent approve agent investigational purpose within last 4 week prior study entry ; Patient know history glucose6phosphate dehydrogenase deficiency ; Patient autoimmune hemolytic anemia ; Patient known Central Nervous System involvement ; Patient active , uncontrolled serious bacterial , viral fungal infection The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>CLL</keyword>
	<keyword>PLL</keyword>
	<keyword>flavopiridol</keyword>
</DOC>